Irina G Obrosova

Summary

Affiliation: Pennington Biomedical Research Center
Country: USA

Publications

  1. Obrosova I, Chung S, Kador P. Diabetic cataracts: mechanisms and management. Diabetes Metab Res Rev. 2010;26:172-80 pubmed publisher
    ..An improved understanding of pathogenetic mechanisms, together with finding effective therapeutic agents, remain highest priority for diabetic cataract-related research and pharmaceutical development. ..
  2. Obrosova I, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens M, et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes. 2005;54:234-42 pubmed
    ..These findings reveal the new beneficial properties of fidarestat, thus further justifying the ongoing clinical trials of this specific, potent, and low-toxic ARI. ..
  3. Obrosova I, Drel V, Kumagai A, Szabo C, Pacher P, Stevens M. Early diabetes-induced biochemical changes in the retina: comparison of rat and mouse models. Diabetologia. 2006;49:2525-33 pubmed
    ..This should be considered when selecting animal models for studying early retinal pathology associated with diabetes. ..
  4. Obrosova I, Ilnytska O, Lyzogubov V, Pavlov I, Mashtalir N, Nadler J, et al. High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes. 2007;56:2598-608 pubmed
  5. Obrosova I, Maksimchyk Y, Pacher P, Agardh E, Smith M, El Remessy A, et al. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. Int J Mol Med. 2010;26:135-42 pubmed
    ..The results identify AR as an important therapeutic target for diseases involving IR injury, and provide the rationale for development of fidarestat and other AR inhibitors. ..
  6. Obrosova I. Diabetes and the peripheral nerve. Biochim Biophys Acta. 2009;1792:931-40 pubmed publisher
  7. Obrosova I. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics. 2009;6:638-47 pubmed publisher
    ..This review describes recent achievements in studying the pathogenesis of diabetic neuropathic pain and sensory disorders in diabetic animal models and developing potential pathogenetic treatments. ..
  8. Obrosova I, Xu W, Lyzogubov V, Ilnytska O, Mashtalir N, Vareniuk I, et al. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med. 2008;44:972-81 pubmed
    ..The results support a rationale for the development of potent and low-toxicity PARP inhibitors and PARP inhibitor-containing combination therapies. ..
  9. Drel V, Xu W, Zhang J, Pavlov I, Shevalye H, Slusher B, et al. Poly(Adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy. Endocrinology. 2009;150:5273-83 pubmed publisher
    ..These findings provide rationale for development and further studies of PARP inhibitors and PARP inhibitor-containing combination therapies. ..

More Information

Publications10

  1. Obrosova I, Stavniichuk R, Drel V, Shevalye H, Vareniuk I, Nadler J, et al. Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies. Am J Pathol. 2010;177:1436-47 pubmed publisher
    ..This should be considered in the selection of endpoints for future clinical trials of 12/15-lipoxygenase inhibitors. ..